Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC9 | O60706 | 15/20 | 0.63 |
| ▸ | ABCC8 | Q09428 | 2/20 | 0.63 |
| ▸ | KCNJ11 | Q14654 | 2/20 | 0.63 |
| ▸ | KCNJ8 | Q15842 | 2/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rilmakalim SCHEMBL9585284 | 1.00 | ABCC9 (0.63) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| Rilmakalim SCHEMBL9293204 | 1.00 | ABCC9 (0.63) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| Rilmakalim SCHEMBL29900877 | 1.00 | ABCC9 (0.63) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| Rilmakalim SCHEMBL9293211 | 1.00 | ABCC9 (0.63) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| Rilmakalim SCHEMBL5043882 | 0.99 | ABCC9 (0.64) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| Rilmakalim SCHEMBL1231447 | 0.99 | ABCC9 (0.64) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| Rilmakalim SCHEMBL4410403 | 0.99 | ABCC9 (0.64) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| Rilmakalim SCHEMBL9295497 | 0.96 | ABCC9 (0.59) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| SCHEMBL9293330 | 0.92 | ABCC9 (0.63) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| SCHEMBL9294498 | 0.92 | ABCC9 (0.63) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 254 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| US-20070254871-A1 | Compounds for the Treatment of Inflammation of the Central Nervous System | NEUROTEC PHARMA, S.L. (ES) | 2007-11-01 | — | — | US | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| EP-1782812-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATION OF THE CENTRAL NERVOUS SYSTEM | Neurotec Pharma, S.L. (ES) | 2007-05-09 | — | — | EP | claimed |
| WO-2007009462-A2 | TREATMENT OF MIGRAINE AND HEADACHES | REGION HOVEDSTADEN V/GLOSTRUP HOSPITAL (DK) | 2007-01-25 | — | — | WO | claimed |
| WO-2006000607-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATION OF THE CENTRAL NERVOUS SYSTEM | NEUROTEC PHARMA, S.L. (ES) | 2006-01-05 | — | — | WO | claimed |
| US-20030045449-A1 | Pharmaceutical combinations for the treatment of neurodegenerative diseases | PFIZER, INC. | 2003-03-06 | — | — | US | claimed |
| US-5364878-A | Antiasthmatics; urogenital disorders | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-11-15 | — | — | US | claimed |
| EP-0351720-B1 | Use of substituted 3,4-dihydro-2H-benzopyrans as medicaments against obstructive disorders of the lung | HOECHST AG (DE) | 1994-08-24 | — | — | EP | claimed |
| EP-0344572-B1 | Composition of angiotensin-converting-enzyme inhibitor with calcium chanell modulators and uses thereof as pharmaceuticals | HOECHST AG (DE) | 1993-12-08 | — | — | EP | claimed |
| EP-0351720-A2 | Use of substituted 3,4-dihydro-2H-benzopyrans as medicaments against obstructive disorders of the lung | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-01-24 | — | — | EP | claimed |
| EP-0344572-A2 | Composition of angiotensin-converting-enzyme inhibitor with calcium chanell modulators and uses thereof as pharmaceuticals | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-12-06 | — | — | EP | claimed |
| JP-2073015-A | — | — | None | — | — | JP | disclosed |
| EP-2841109-B1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA AS (DK) | 2026-04-15 | — | — | EP | disclosed |
| EP-0344572-A2 | Composition of angiotensin-converting-enzyme inhibitor with calcium chanell modulators and uses thereof as pharmaceuticals | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-12-06 | — | — | EP | disclosed |
| EP-0277612-A2 | Substituted 3,4-dihydro-2H-benzopyranes, process for their preparation, their use and pharmaceutical preparations based on these compounds | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-08-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045449-A1 | Pharmaceutical combinations for the treatment of neurodegenerative diseases | GRIN3A, GRIN1, CHRNA10 | ABCC9 2860/4885ABCC8 3104/4885KCNJ11 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.